司美格鲁肽联合卡格列净治疗肥胖型2型糖尿病的效果

Effect of Rosmeglutide Combined with Caragliflozin in the Treatment of Obese Type 2 Diabetes Mellitus

目的:分析肥胖型2型糖尿病治疗中联合司美格鲁肽+卡格列净治疗的效果。方法:选择于2022年1月—2023年4月,商城县人民医院内分泌科收治的肥胖型2型糖尿病患者100例作为研究对象,随机分为对照组和观察组,每组50例。对照组予以司美格鲁肽治疗,观察组予以司美格鲁肽+卡格列净治疗,比较两组肥胖指标、实验室指标及不良反应。结果:治疗后,观察组体质量、WC、BMI、FBG、HbAlc、HOMA-IR水平低于对照组,FINS、FCP高于对照组(P<0.05);观察组不良反应发生率(15.00%)与对照组(6.00%)比较,差异无统计学意义(P>0.05)。结论:采用司美格鲁肽联合卡格列净治疗可有效改善肥胖型2型糖尿病患者的肥胖、血糖等指标,且无明显不良反应,值得临床应用。

Objective:To analyze the effect of combined treatment of obese type 2 diabetes mellitus with semeglutide+cagliflozin.Methods:From January 2022 to April 2023,100 obese patients with type 2 diabetes mellitus admitted to the Department of Endocrinology of Shangcheng County People's Hospital were selected as the research objects and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with Semeglutide,and the observation group was treated with Semeglutide+Kagliflozin.The obesity indexes,laboratory indexes and adverse reactions were compared between the two groups.Results:After treatment,the body mass,WC,BMI,FBG,HbAlc,and HOMA-IR levels in the observation group were lower than those in the control group,while FINS and FCP were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group(15.00%)and the control group(6.00%)(P>0.05).Conclusion:Semeglutide combined with caspagliflozin can effectively improve the obesity,blood glucose and other indicators of obese patients with type 2 diabetes,and has no obvious adverse reactions,which is worthy of clinical application.